Momchilo Vuyisich

Dr. Momchilo Vuyisich

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2021 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
HTHal Tily
Hal Tily
Eric PatridgeEric Patridge
Eric Patridge
YCYing Cai
Ying Cai
VGVishakh Gopu
Vishakh Gopu
SGStephanie Gline
Stephanie Gline
GBGuru Banavar
Guru Banavar
Limiting postprandial glycemic response (PPGR) is an important intervention in reducing the risk of chronic metabolic diseases and has been shown to impart significant health benefits in people with elevated levels of blood sugar. In this study, we collected gut microbiome activity data by assessing the metatranscriptome, and we measured the glycemic responses of 550 adults who consumed more than 30,000 meals, collectively, from omnivore or vegetarian/gluten-free diets. We demonstrate that gut microbiome activity, anthropometric factors, and food macronutrients modulate individual variation in glycemic response. We employ two predictive models, including a mixed-effects linear regression model (R = 0.77) and a gradient boosting machine model (Rtrain = 0.80/R2train = 0.64; Rtest = 0.64/R2test = 0.40), which demonstrate variation in PPGR between individuals when ingesting the same foods. All features in the final mixed-effects linear regression model were significant (p < 0.05) except for two features which were retained as suggestive: glutamine production pathways (p = 0.08) and the interaction between tyrosine metabolizers and carbs (p = 0.06). We introduce molecular functions as features in these two models, aggregated from microbial activity data, and show their statistically significant contributions to glycemic control. In summary, we demonstrate for the first time that metatranscriptomic activity of the gut microbiome is correlated with PPGR among adults.

1 October 2019 in International Journal of Genomics
Verified
Journal Article
Open access
PDF file
AHAndrew Hatch
Andrew Hatch
JHJames Horne
James Horne
RTRyan Toma
Ryan Toma
BTBrittany L. Twibell
Brittany L. Twibell
KSKalie M. Somerville
Kalie M. Somerville
MVMomchilo Vuyisich
Momchilo Vuyisich
A functional readout of the gut microbiome is necessary to enable precise control of the gut microbiome’s functions, which support human health and prevent or minimize a wide range of chronic diseases. Stool metatranscriptomic analysis offers a comprehensive functional view of the gut microbiome, but despite its usefulness, it has rarely been used in clinical studies due to its complexity, cost, and bioinformatic challenges. This method has also received criticism due to potential intrasample variability, rapid changes, and RNA degradation. Here, we describe a robust and automated stool metatranscriptomic method, called Viomega, which was specifically developed for population-scale studies. Viomega includes sample collection, ambient temperature sample preservation, total RNA extraction, physical removal of ribosomal RNAs (rRNAs), preparation of directional Illumina libraries, Illumina sequencing, taxonomic classification based on a database of >110,000 microbial genomes, and quantitative microbial gene expression analysis using a database of ~100 million microbial genes. We applied this method to 10,000 human stool samples and performed several small-scale studies to demonstrate sample stability and consistency. In summary, Viomega is an inexpensive, high-throughput, automated, and accurate sample-to-result stool metatranscriptomic technology platform for large-scale studies and a wide range of applications.

10 August 2020 in BioTechniques
Verified
Journal Article
Open access
RTRyan Toma
Ryan Toma
NDNathan Duval
Nathan Duval
BPBenjamin Pelle
Benjamin Pelle
MPMatthew M Parks
Matthew M Parks
VGVishakh Gopu
Vishakh Gopu
MVMomchilo Vuyisich
Momchilo Vuyisich
To prevent and treat chronic diseases, including cancer, a global application of systems biology is needed. We report here a whole blood transcriptome test that needs only 50 μl of capillary (finge... METHOD SUMMARY This report describes an important improvement to whole blood transcriptome analysis. While current methods are complicated and expensive, the method reported here includes at-home s...

23 November 2023 in American Journal of Lifestyle Medicine
Verified
Journal Article
Closed access
JCJanelle Connell
Janelle Connell
RTRyan Toma
Ryan Toma
CHCleo Han-Chen Ho
Cleo Han-Chen Ho
NSNan Shen
Nan Shen
PMPedro Moura
Pedro Moura
MVMomchilo Vuyisich
Momchilo Vuyisich
Many studies have shown that foods and nutritional ingredients play an important role in healthy human homeostasis, either directly or via the microbiome. We have developed an objective, integrated, and automated approach to personalized food and supplement recommendations that is powered by artificial intelligence and individualized molecular data from the gut microbiome, the human host, and their interactions. The process starts with a clinically validated transcriptomic analysis of a person’s stool (and some cases also blood) sample. These molecular data are converted into personalized nutritional recommendations (foods and supplements) using algorithms derived from clinical research studies and domain knowledge. We describe an application of our precision nutrition technology platform to human populations with irritable bowel syndrome (IBS), depression, anxiety, and type 2 diabetes (T2D). In these pilot interventional studies, our precision nutrition program achieved significant improvements in clinical outcomes of IBS (39% for severe IBS), depression (31% for severe depression), anxiety (31% for severe anxiety), and the risk score for T2D (>30% reduction relative to the control arm). These data support the integration of data-driven precision nutrition into the standard of care.

18 September 2025 in ACR Open Rheumatology
Verified
Journal Article
Open access
SESharon Erdrich
Sharon Erdrich
Ingrid C. GelissenIngrid C. Gelissen
Ingrid C. Gelissen
RTRyan Toma
Ryan Toma
MVMomchilo Vuyisich
Momchilo Vuyisich
Joanna E HarnettJoanna E Harnett
Joanna E Harnett
Objective: To describe the composition of the gut microbiota of women living with fibromyalgia, compared with controls, and examine the relationship between fecal microbiota and clinical features of fibromyalgia.Methods: New Zealand women meeting American College of Rheumatology fibromyalgia criteria and age‐matched controls provided fecal samples and completed validated surveys assessing pain, disorders of gut–brain interaction (DGBI), headaches, sleep quality, oral health, cognition, anxiety, depression, diet, and quality of life. Metatranscriptomic analysis identified phyla, genera, and species in fecal samples. Correlation coefficients were calculated for each α‐diversity metric against clinical variables. Welch's t‐test or Wilcoxon rank test was applied for binary clinical variables. Generalized linear models analyzed associations in the fibromyalgia group, adjusting for age, body mass index, and diet. Data processing and analysis used R version 4.2.1, with the Benjamini–Hochberg formula controlling for false discovery rate at ≤0.10 to minimize type 1 error risk.Results: No statistically significant differences were seen in the microbial expression in fecal samples of women with fibromyalgia (n = 104) compared with controls (n = 52). Significant associations among three species from the Bacteroidetes phylum and cognitive impairment were observed. Fusobacteriota was significantly associated with Rome IV(B) DGBI, specifically epigastric pain syndrome. A strong association was observed between oral microbiota in feces and upper gastrointestinal DGBI, indicating both negative and positive correlations in this population.Conclusion: No overall differences in fecal microbial expression were found in women with fibromyalgia. However, Bacteroidetes and Fusobacteriota phyla were significantly associated with cognitive impairment and epigastric pain syndrome, respectively. image

6 August 2024 in NeuroSci
Verified
Journal Article
Open access
PDF file
MCMark Cannon
Mark Cannon
RTRyan Toma
Ryan Toma
SGSri Ganeshan
Sri Ganeshan
EVEmmery de Jesus Alvarez Varela
Emmery de Jesus Alvarez Varela
MVMomchilo Vuyisich
Momchilo Vuyisich
GBGuru Banavar
Guru Banavar
Autism rates have been reported to be increasing rapidly in industrialized societies. The pathology most often combines neurological symptoms associated with language and social impairments with gastrointestinal symptoms. This study aimed to measure differences in oral metatranscriptome and mitochondrial health between ASD children and neurotypical USA and Colombia (“Blue Zone”) children. In addition, this study aimed to determine whether using prebiotics and probiotics would change the oral microbiome and mitochondrial health of ASD children. Buccal swabs and saliva samples were obtained from 30 autistic individuals (USA) at three intervals: prior to intervention, post-prebiotic, and post-probiotic. In addition, a subject component who were neurotypical, which included individuals from the USA (30) and Colombia (30), had buccal swabbing and salivary sampling performed for metatranscriptomic and mitochondrial comparison. Significant differences were observed in the temporal data, demonstrating shifts that interventions with probiotics and polyols may have precipitated. Particular bacterial strains were significantly more prevalent in the autism group, including a strain that reduced neurotransmitter levels via enzymatic degradation. This supports the hypothesis that the microbiome may influence the occurrence and degree of autism. Verbal skills increased in six of the 30 ASD subjects following xylitol and three more after probiotic supplementation, according to both parental reports and the subjects’ healthcare providers.